On January 22, 2021, the Board of Directors of Inogen, Inc. appointed Nabil Shabshab to serve as President and Chief Executive Officer (CEO") of the Company, effective February 8, 2021. In addition, on January 22, 2021, the Board, upon recommendation of the Nominating and Governance Committee, appointed Mr. Shabshab to serve as a Class II director of the Company, effective February 8, 2021, with a term expiring at the annual meeting of stockholders to be held in 2022. Mr. Shabshab will succeed Scott Wilkinson, who had previously announced that he is retiring from the positions of President, CEO, and as a director. Mr. Wilkinson's retirement as an officer and director of the Company is effective February 8, 2021. Most recently, Mr. Shabshab, 56, served as Worldwide President of Diabetes Care and Digital Health at Becton Dickinson and Company, since August 2017.
Inogen, Inc. is a medical technology company offering respiratory products for use in the homecare setting. The Company supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Its Inogen One systems reduces patients' reliance on stationary concentrators and oxygen compressed gas tanks. Its Inogen Connect is a wireless connectivity platform for the Inogen One G4, Inogen One G5 and Rove 6 consisting of a front-end mobile application for use by long-term oxygen therapy users and a back-end database portal for use by homecare providers. It also offers Simeox, which is an airway clearance device.
INOGEN, INC. 
